Cost-Effectiveness of Brodalumab Compared with Available Biologic Therapies for Moderate-to-Severe Plaque Psoriasis in Adults in the Brazilian Supplementary Health System

Authors

  • Paulo Antônio Oldani Felix Serviço de Dermatologia, Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brasil
  • Marcos Santos Departamento de Rádio-Oncologia, Grupo CONFIAR, Goiânia, GO, Brasil
  • Aline Maria Fortuna Magalhães LEO Pharma Ltda, São Paulo, SP, Brasil
  • Lucas Giglio Colli LEO Pharma Ltda, São Paulo, SP, Brasil
  • Daniel Henrique Oliveira Fonseca LEO Pharma Ltda, São Paulo, SP, Brasil
  • Giovana de Santana Gouveia LEO Pharma Ltda, São Paulo, SP, Brasil
  • Guilherme Muzy Clínica Muzy, São Paulo, SP, Brasil

DOI:

https://doi.org/10.66305/jbas.v5i1.32

Keywords:

Cost-Effectiveness, Brodalumab, Psoriasis

Abstract

The study evaluates the cost-effectiveness of brodalumab compared with other biologic therapies available for the treatment of moderate-to-severe plaque psoriasis in adults in the Brazilian supplementary health system.

Downloads

Published

2026-02-06

How to Cite

Antônio Oldani Felix, P., Santos, M., Maria Fortuna Magalhães, A., Giglio Colli, L., Henrique Oliveira Fonseca, D., de Santana Gouveia, G., & Muzy, G. (2026). Cost-Effectiveness of Brodalumab Compared with Available Biologic Therapies for Moderate-to-Severe Plaque Psoriasis in Adults in the Brazilian Supplementary Health System. Brazilian Journal of Health Auditing, 5(1), 3–15. https://doi.org/10.66305/jbas.v5i1.32

Issue

Vol. 5 No. 1 (2025): Jornal Brasileiro de Auditoria em Saúde

Section

Original articles

License

Copyright (c) 2026 Journal Brasileiro de Auditoria em Saúde

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Os artigos publicados não expressam necessariamente a opinião da revista e são de responsabilidade exclusiva dos autores.